MET and metastatic malignant neoplasm: Two highly studied RTK signaling pathways, the epidermal growth factor receptor (EGFR; Entrez Gene: 1956) pathway and the hepatocyte growth factor receptor (HGFR or c-Met; Entrez Gene: 4233) pathway, have been identified as therapeutic targets for preventing and treating metastatic cancer [9–12].